Back to Search
Start Over
Very low mutation burden is a feature of inflamed recurrent glioblastomas responsive to cancer immunotherapy
- Source :
- Nature Communications, Vol 12, Iss 1, Pp 1-7 (2021)
- Publication Year :
- 2021
- Publisher :
- Nature Portfolio, 2021.
-
Abstract
- Recurrent glioblastomas (rGBM) have dismal outcomes, but long-term survival has been observed in subsets of patients after immunotherapy. Here the authors report a positive association between low tumor mutation burden, inflammatory gene signatures, and survival after immunotherapy in rGBM patients.
- Subjects :
- Science
Subjects
Details
- Language :
- English
- ISSN :
- 20411723
- Volume :
- 12
- Issue :
- 1
- Database :
- Directory of Open Access Journals
- Journal :
- Nature Communications
- Publication Type :
- Academic Journal
- Accession number :
- edsdoj.9b4f7304b8f54613b5f0b6626698e589
- Document Type :
- article
- Full Text :
- https://doi.org/10.1038/s41467-020-20469-6